The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

The brokerage's optimism stems from an expected operational turnaround for Biocon, driven by key biosimilar launches and a recovery in generics sales. HSBC highlighted several factors that could ...

Biocon, the mid-cap biopharma company ... estimated to grow 25 per cent YoY to Rs 3,690 crore for the quarter under review. The same stood at Rs 2,942 crore in the corresponding period of the ...

Save your favourite. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement.

India's Biocon has partnered with US-based Mylan to sell Indian-made biogenerics globally. Bangalore-based Biocon sees the collaboration with Mylan, the world's third-largest generics producer ...

Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.) ...

Kiran Mazumdar-Shaw, Chairperson of major drugmaker Biocon Ltd., urged the government to eliminate tax on drugs for cancer treatment and for chronic and rare diseases, ahead of the budget 2025 ...

Biocon Pharma, a subsidiary of Biocon, got China’s approval for Tacrolimus capsules (0.5mg, 1mg, 5mg). The immunosuppressant helps prevent organ rejection in transplant patients and strengthens ...